Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort.
Aged
COVID-19
/ complications
Cohort Studies
Echocardiography
/ methods
Exercise Test
/ methods
Exercise Tolerance
/ immunology
Female
Follow-Up Studies
France
Humans
Lung
/ physiopathology
Male
Middle Aged
Pneumonia
/ etiology
Prospective Studies
Respiratory Function Tests
/ methods
Respiratory Insufficiency
/ etiology
COVID-19
Cardiopulmonary exercise testing
Pulmonary function
SARS-CoV-2
Sarcopenia
Skeletal muscle
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
22 Mar 2022
22 Mar 2022
Historique:
received:
15
10
2021
accepted:
06
03
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
Patient hospitalized for coronavirus disease 2019 (COVID-19) pulmonary infection can have sequelae such as impaired exercise capacity. We aimed to determine the frequency of long-term exercise capacity limitation in survivors of severe COVID-19 pulmonary infection and the factors associated with this limitation. Patients with severe COVID-19 pulmonary infection were enrolled 3 months after hospital discharge in COVulnerability, a prospective cohort. They underwent cardiopulmonary exercise testing, pulmonary function test, echocardiography, and skeletal muscle mass evaluation. Among 105 patients included, 35% had a reduced exercise capacity (VO Three months after a severe COVID-19 pulmonary infection, more than one third of patients had an impairment of exercise capacity which was associated with a reduced pulmonary function, a reduced skeletal muscle mass and function but without any significant impairment in cardiac function.
Sections du résumé
BACKGROUND
BACKGROUND
Patient hospitalized for coronavirus disease 2019 (COVID-19) pulmonary infection can have sequelae such as impaired exercise capacity. We aimed to determine the frequency of long-term exercise capacity limitation in survivors of severe COVID-19 pulmonary infection and the factors associated with this limitation.
METHODS
METHODS
Patients with severe COVID-19 pulmonary infection were enrolled 3 months after hospital discharge in COVulnerability, a prospective cohort. They underwent cardiopulmonary exercise testing, pulmonary function test, echocardiography, and skeletal muscle mass evaluation.
RESULTS
RESULTS
Among 105 patients included, 35% had a reduced exercise capacity (VO
CONCLUSION
CONCLUSIONS
Three months after a severe COVID-19 pulmonary infection, more than one third of patients had an impairment of exercise capacity which was associated with a reduced pulmonary function, a reduced skeletal muscle mass and function but without any significant impairment in cardiac function.
Identifiants
pubmed: 35317815
doi: 10.1186/s12931-022-01977-z
pii: 10.1186/s12931-022-01977-z
pmc: PMC8938727
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Subventions
Organisme : Université Paris-Est Créteil Val-de-Marne
ID : COVulnerability Cohort
Informations de copyright
© 2022. The Author(s).
Références
J Korean Med Sci. 2018 May 10;33(24):e169
pubmed: 29892209
Int J Chron Obstruct Pulmon Dis. 2017 Feb 20;12:669-675
pubmed: 28255238
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
Thorax. 2005 May;60(5):401-9
pubmed: 15860716
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34210791
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34385265
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
J Am Soc Echocardiogr. 2013 Mar;26(3):297-306
pubmed: 23265440
J Med Virol. 2021 Jan;93(1):35-37
pubmed: 32470146
Eur Respir J. 2020 Aug 6;56(2):
pubmed: 32554533
Respiration. 2007;74(5):511-6
pubmed: 16960439
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Am J Cardiol. 2014 Apr 1;113(7):1211-6
pubmed: 24507172
Ageing Res Rev. 2020 Dec;64:101185
pubmed: 32992047
Eur Respir Rev. 2020 Oct 5;29(157):
pubmed: 33020069
J Physiol. 2020 Feb;598(3):599-610
pubmed: 31856306
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Medicine (Baltimore). 2020 Nov 20;99(47):e23315
pubmed: 33217868
Metabolism. 2020 Dec;113:154378
pubmed: 33002478
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Respir J. 1997 Nov;10(11):2662-89
pubmed: 9426113
Circ Cardiovasc Imaging. 2019 Dec;12(1):e008122
pubmed: 30632389
Nutrients. 2020 Jan 14;12(1):
pubmed: 31947528
Eur Respir J. 2004 Sep;24(3):436-42
pubmed: 15358703
PLoS One. 2015 Mar 18;10(3):e0121539
pubmed: 25785739
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
J Clin Med. 2020 Aug 04;9(8):
pubmed: 32759719
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33926969
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1164-1176
pubmed: 32862514
Eur Respir J. 1993 Mar;6 Suppl 16:5-40
pubmed: 24576915
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076
Respir Med Res. 2021 Nov;80:100822
pubmed: 34242974
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303539